{2-[(6-Chloropyridin-3-yl)oxy]ethyl}dimethylamine | 850408-72-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: {2-[(6-Chloropyridin-3-yl)oxy]ethyl}dimethylamine
• 英文别名: 2-(6-chloropyridin-3-yl)oxy-N,N-dimethylethanamine
• CAS: 850408-72-9
• 化学式: C₉H₁₃ClN₂O
• 分子量: 200.668
• InChiKey: WHBHRCPKWRFJKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  {2-[(6-Chloropyridin-3-yl)oxy]ethyl}dimethylamine 在 palladium on activated charcoal 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 氢气 、 三乙胺 作用下， 以 乙醇 、 水 、 异丙醇 为溶剂， 生成 N,N-dimethyl-2-[6-(2-phenylethyl)pyridin-3-yl]oxyethanamine
  参考文献：
  名称：

  Aryloxyethylamines: Binding at α7 nicotinic acetylcholine receptors

  摘要：

  Structure-affinity relationships for the binding of 3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine (AXPQ) at alpha 7 nACh receptors were investigated due to its close structural similarity to a known alpha 7 antagonist. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.080
• 作为产物：
  描述：

  2-氯-5-羟基吡啶 、 2-氯-N,N-二甲基乙胺 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 {2-[(6-Chloropyridin-3-yl)oxy]ethyl}dimethylamine
  参考文献：
  名称：

  Quaternary ammonium 3-(aminoethoxy)pyridines as antinociceptive agents

  摘要：

  Quaternization via N-methylation of the terminal amines of a series of 3-(dialkylaminoethoxy)pyridines resulted in analogues that displayed up to 50-60-fold enhanced affinity for nicotinic acetylcholinergic (nACh) receptors. Several of these compounds displayed antinociceptive properties in mice using the tail-flick assay and serve as possible leads for the development of novel analgesic agents. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00585-7

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2010080503A1

  公开（公告）日：2010-07-15

  In one aspect, the present invention provides for a compound of Formula I; in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

  在一个方面，本发明提供了一种具有式I的化合物；其中变量X1a、X1b、X1c、X1d、Q、A、R1、B、L、E和下标m和n的含义如本文所述。在另一个方面，本发明提供了包括式I化合物的药物组合物，以及使用式I化合物治疗由Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的表达或过度表达所特征的疾病和状况（例如癌症、血小板增多症等）的方法。
• HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：Baell Jonathan Bayldon

  公开号：US20100210622A1

  公开（公告）日：2010-08-19

  In one aspect, the present invention provides for a compound of Formula I in which the variable X 1a , X 1b , X 1c , X 1d , Q, A, R 1 , B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-x L proteins.

  在一个方面，本发明提供了一种式子为I的化合物，其中变量X1a，X1b，X1c，X1d，Q，A，R1，B，L，E和下标m和n的含义如此处所述。在另一个方面，本发明提供了包含式子I化合物的制药组合物，以及使用式子I化合物治疗由Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的表达或过表达所特征的疾病和病状（例如癌症，血小板增多症等）的方法。
• Heterocyclic compounds and methods of use
  申请人：Genentech, Inc.

  公开号：US08232273B2

  公开（公告）日：2012-07-31

  In one aspect, the present invention provides for a compound of Formula I in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

  在一个方面，本发明提供了一种公式I的化合物，其中变量X1a、X1b、X1c、X1d、Q、A、R1、B、L、E和下标m和n的含义如此处所述。在另一个方面，本发明提供了包含公式I化合物的制药组合物，以及使用公式I化合物治疗表达或过度表达Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的疾病和状况（例如癌症、血小板增多症等）的方法。
• Synthesis and biological evaluation of pyridine-modified analogues of 3-(2-Aminoethoxy)pyridine as novel nicotinic receptor ligands
  作者：Nan-Horng Lin、Liming Dong、William H Bunnelle、David J Anderson、Michael D Meyer

  DOI：10.1016/s0960-894x(02)00740-0

  日期：2002.11

  Analogues of the potent nicotinic receptor agonist 3-(2-aminoethoxy)pyridine substituted at the 5' and 6'-positions of the pyridine ring were synthesized and tested in vitro for nicotinic receptor binding activity (displacement of [H-3](-)cytisine from whole rat brain synaptic membranes). The substituted analogues exhibited K-i values ranging from 0.076 to 319 nM compared to a K-i value of 26 nM for compound 1. Among the compounds tested, 5'-vinyl-6'-chloro substituted I was the most potent. (C) 2002 Elsevier Science Ltd. All rights reserved.
• US8232273B2
  申请人：——

  公开号：US8232273B2

  公开（公告）日：2012-07-31